{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T19:56:44Z","timestamp":1762113404436,"version":"3.44.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"8-9","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.annder.2013.02.031","type":"journal-article","created":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T13:45:42Z","timestamp":1371649542000},"page":"510-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effets ind\u00e9sirables cutan\u00e9s des inhibiteurs de BRAF\u00a0: revue syst\u00e9matique"],"prefix":"10.1016","volume":"140","author":[{"given":"V.","family":"Sibaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Lamant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Maisongrosse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Delord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2013.02.031_bib0005","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.02.031_bib0010","first-page":"6522","article-title":"BRAF-dependent regulation of the MEK-1\/mitogen-activated protein kinase pathway in PC12\u00a0cells and regulation by cyclic AMP","volume":"14","author":"Vaillancourt","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.annder.2013.02.031_bib0015","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.annder.2013.02.031_bib0020","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ejca.2011.06.052","article-title":"New drugs in melanoma: it's a whole new world","volume":"47","author":"Eggermont","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annder.2013.02.031_bib0025","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.02.031_bib0030","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Eng J Med"},{"key":"10.1016\/j.annder.2013.02.031_bib0035","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1\u00a0dose-escalation trial","volume":"379","author":"Falschook","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2013.02.031_bib0040","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3\u00a0randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2013.02.031_bib0045","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.02.031_bib0050","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaad.2012.06.045","article-title":"Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma","volume":"67","author":"Boyd","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.02.031_bib0055","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/annonc\/mds292","article-title":"Cutaneous effects of BRAF inhibitor therapy: a case series","volume":"24","author":"Mattei","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annder.2013.02.031_bib0060","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1053\/j.seminoncol.2012.01.009","article-title":"Advances in the management of cutaneous toxicities of targeted therapies","volume":"39","author":"Robert","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.annder.2013.02.031_bib0065","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1684\/bdc.2011.1457","article-title":"Dermatologic side effects induced by new angiogenesis inhibitors","volume":"98","author":"Sibaud","year":"2011","journal-title":"Bull Cancer"},{"key":"10.1016\/j.annder.2013.02.031_bib0070","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1001\/archderm.144.7.886","article-title":"Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor","volume":"144","author":"Autier","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.02.031_bib0075","first-page":"521","article-title":"Dermatological findings in 61\u00a0mutation-positive individuals with cardiofaciocutaneous syndrome","volume":"164","author":"Siegel","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2013.02.031_bib0080","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2133.2011.10744.x","article-title":"Dermatological phenotype in Costello syndrome: consequences of Ras dysregulation in development","volume":"166","author":"Siegel","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2013.02.031_bib0085","series-title":"Melanoma Conference, EORTC","article-title":"Cutaneous side effects associated with the BRAF inhibitor vemurafenib: a prospective study of 42\u00a0patients","author":"Boussemart","year":"2012"},{"key":"10.1016\/j.annder.2013.02.031_bib0090","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-2133.2012.11155.x","article-title":"Manifestations of Dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma","volume":"167","author":"Anforth","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2013.02.031_bib0095","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/bjd.12010","article-title":"Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities","volume":"167","author":"Sinha","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.annder.2013.02.031_bib0100","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.02.031_bib0105","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jaad.2012.04.008","article-title":"Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study","volume":"67","author":"Chu","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.annder.2013.02.031_bib0110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.02.031_bib0115","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.02.031_bib0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1158\/1078-0432.CCR-11-1344","article-title":"Skin tumors induced by sorafenib; paradoxical RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53\u00a0and TGFBR1","volume":"18","author":"Arnault","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annder.2013.02.031_bib0125","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1755-148X.2012.01031.x","article-title":"Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking braf inhibitors","volume":"25","author":"Anforth","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.annder.2013.02.031_bib0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Eng J Med"},{"key":"10.1016\/j.annder.2013.02.031_bib0135","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600\u00a0mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.02.031_bib0140","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1200\/JCO.2011.39.8594","article-title":"Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib","volume":"30","author":"Anforth","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annder.2013.02.031_bib0145","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archdermatol.2011.3080","article-title":"Photodynamic therapy for multiple eruptive keratoacantomas associatecd with vemurafenib treatment for metastatic melanoma","volume":"148","author":"Alloo","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.02.031_bib0150","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1001\/archdermatol.2012.125","article-title":"Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway","volume":"148","author":"Huang","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.02.031_bib0155","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5070\/D38W90X9ZB","article-title":"A case of vemurafenib-induced keratosis pilaris-like eruption","volume":"18","author":"Wang","year":"2012","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.annder.2013.02.031_bib0160","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1056\/NEJMc1114329","article-title":"Vemurafenib sensitivity skin reaction after ipilimumab","volume":"366","author":"Harding","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.02.031_bib0165","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/archdermatol.2012.758","article-title":"Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by kaposi varicelliform eruption","volume":"148","author":"Gupta","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.02.031_bib0170","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14740338.2011.546342","article-title":"Capecitabine and hand-foot syndrome","volume":"10","author":"Saif","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.annder.2013.02.031_bib0175","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","article-title":"Evolving strategies for the management of hand-foot syndrome skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib","volume":"13","author":"Lacouture","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.annder.2013.02.031_bib0180","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1056\/NEJMc1113752","article-title":"Ultraviolet A and photosensitivity during vemurafenib therapy","volume":"366","author":"Dummer","year":"2012","journal-title":"N Eng J Med"},{"key":"10.1016\/j.annder.2013.02.031_bib0185","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.annder.2012.12.012","article-title":"Troubles pigmentaires induits pas les agents anticanc\u00e9reux. Premi\u00e8re partie\u00a0: chimioth\u00e9rapies","volume":"140","author":"Sibaud","year":"2013","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.annder.2013.02.031_bib0190","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1001\/archderm.144.6.820","article-title":"Sorafenib-induced eruptive melanocytic lesions","volume":"144","author":"Kong","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.02.031_bib0195","first-page":"1","article-title":"Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy","volume":"20","author":"Haenssle","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.02.031_bib0200","first-page":"1448","article-title":"Vemurafenib in melanoma with BRAF V600E mutation","volume":"13","author":"Dalle","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.annder.2013.02.031_bib0205","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/archdermatol.2011.2842","article-title":"Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management","volume":"148","author":"Zimmer","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.annder.2013.02.031_bib0210","series-title":"Cutaneous side effects induced by targeted anticancer therapies: a new dermatology","first-page":"41","article-title":"Dermatologic manifestations of angiogenesis inhibitors","author":"Sibaud","year":"2010"},{"key":"10.1016\/j.annder.2013.02.031_bib0215","article-title":"Vemurafenib and radiosensitization","author":"Boussemard","year":"2013","journal-title":"Arch Dermatol"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963813008028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963813008028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:00:46Z","timestamp":1758970846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963813008028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":43,"journal-issue":{"issue":"8-9","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0151963813008028"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2013.02.031","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effets ind\u00e9sirables cutan\u00e9s des inhibiteurs de BRAF\u00a0: revue syst\u00e9matique","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2013.02.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}